cyrilzakka/clinical-trials huggingface dataset:
Midazolam Sedation in Dentally Anxious Patients

Use lay language.

To compare patient level of cooperation during dental care under conscious sedation with midazolam according to the administration route

The progress of the study is described below:

Session 1: intravenous administration of midazolam. Establishment of the individual dose.

Randomisation.

Session 2 :

Group A : oral administration of midazolam : the dose administered is twice the individual dose determined in session 1.

Group B : intravenous administration of midazolam at the individual dose determined in session 1.

Session 3 : reversal of the procedures :

Group A : intravenous administration of midazolam at the individual dose determined in session 1.

Group B : oral administration of midazolam : the dose administered is twice the individual dose determined in session 1.

Eligibility Criteria:
Inclusion Criteria:

* - Patient between 8 and 60 years, regardless of gender
* Patient in the American Society of Anesthesiologists (ASA) category I ou II.
* Patient in need of multiple dental care, referred to the Unit of Special Care Dentistry for cooperation difficulties
* Patients directed to conscious sedation under midazolam because they cannot be approached for more than a very brief examination, or following failure to treat under inhalation sedation (50% N2O/O2), or following poor cooperation during treatment under inhalation sedation (poor cooperation is defined as a score of 3 or more on the French modified version of the Venham scale), or following good cooperation during short and simple treatment under inhalation sedation but in need of more complex rehabilitation.
* Written consent signed by the patient or his legal guardian
* Patient accompanied by an accountable person

Exclusion Criteria:

* - Patient below 8 years or over 60 years-old
* Patient in the American Society of Anesthesiologists (ASA) category III or more
* Patient having accepted dental treatment without premedication or sedation, and without declaring dental anxiety, during the month prior to the appointment
* Patient having received an anxiolytic premedication in the 24 hours preceding the dental care session
* Patient already treated under midazolam sedation less than a week ago
* Any medical contraindication to the use of midazolam
Comparison Between Clavipectoral Fascia Block & Interscalene Brachial Plexus Block As Regard Adequacy of Anesthesia in Clavicle Surgeries

A newer technique called clavipectoral fascial plane block (CPB), introduced by Valdés-Vilches in 2017, involves injecting local anesthetic under ultrasound guidance between the clavipectoral fascia and periosteum at the injury site. This method offers a promising alternative for effective regional anesthesia in clavicular fracture surgeries. this study is aim to Comparison Between Use of Ultrasound guided Clavipectroal fascia block ( CPB ) \& interscalene brachial plexus block ( ISBP ) As Regard Adeqacy of Anesthesia in clavicle Fracture

Clavicle fractures represent 2.6% of all fractures and are commonly seen in emergency and surgical settings, particularly among young men due to sports or traffic incidents, predominantly affecting the mid-clavicle. Surgical intervention often yields better functional outcomes compared to conservative treatment. While general anesthesia is an option, it carries risks such as nausea, vomiting, and increased costs for patients. In contrast, regional anesthesia can effectively manage pain while minimizing complications associated with general anesthesia.

The supraclavicular nerve innervates the skin above the clavicle, but the sensory innervation of the clavicle itself remains debated. A combination of superficial cervical plexus block (SCPB) and interscalene brachial plexus block (ISBP) is frequently employed during clavicle fracture surgeries. The brachial plexus includes nerves from C5-8 and T1, while the cervical plexus comprises branches from both deep and superficial cervical structures. Although this combination can effectively address pain management during surgery, ISBP may lead to complications like diaphragmatic paralysis due to phrenic nerve involvement.

Eligibility Criteria:
Inclusion Criteria:

* . Patients who have isolated clavicle surgery. American Society of Anesthesiologists (ASA) classification I-II

Exclusion Criteria:

* 1.Patient with Major Trauma Insult " Brain \\ chest \\ Abdomen " 2.History of bleeding diathesis 3.Patients receiving anticoagulant treatment, 4.Patients known local anesthetics and opioid allergy, 5.Infection of the skin at the site of the needle puncture, 6.Pregnant or lactating females, 7.Patients who do not accept the procedure
Allergens in Inner-City Schools and Childhood Asthma

Asthma is a disease that affects more than 12% of Americans under the age of 18 for over 14 million missed school days per year, and is the number one cause of school absences in America. Elementary school children spend 6 to 10 hours a day in school, and most of that time is spent in one classroom. The goals of this project are to provide an understanding of exposure risk factors specific to the classroom. This is critical, because the classroom environment could potentially be considered as an effective target for prevention of inner-city asthma morbidity by reducing exposures to many symptomatic children through an intervention in the school classrooms.


Eligibility Criteria:
Inclusion Criteria:

* Grades K-8 the school year following spring recruitment (Ages 4-15)
* Attend one of the schools in the fall where permission obtained for classroom sampling.
* Able to provide assent and parent/guardian able to provide informed consent Physician-Diagnosed asthma AND Wheezing in the previous 12 months

Exclusion Criteria:

* Significant pulmonary diseases other than asthma that might influence test results or pose risks (e.g., cystic fibrosis, sarcoidosis, bronchiectasis)
* Cardiovascular disease that requires daily medication
* Taking a beta blocker
* Active smoker
* Unable to follow through with study visit or complete study procedures
Comparison of Autogenous Periosteal Pedicle Graft and Collagen Membrane in Management of Periodontal Intrabony Defects

A clinical and radiographic evaluation of autogenous periosteal pedicle graft in comparison with collagen membrane for management of periodontal intrabony defects.

Twenty patients suffering from advanced chronic periodontitis were included in this randomized controlled clinical trial. Each subject contributed matched pairs of two- or three-walled intrabony defects. Each pair of periodontal defects were randomly assigned into the experimental group; periosteal pedicle graft guided tissue membrane or the positive control group; bioresorbable collagen guided tissue regeneration membrane. Clinical and radiographic parameters were recorded at baseline and at 6 months postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* Severe chronic periodontitis patients with at least two sites with pocket depth ≥ 6 mm and clinical attachment level ≥ 5 mm, with radiographic evidence of bone loss 2- or 3-wall intrabony defect depth ranging from 3 to 6 mm as detected in periapical radiographs
* The facial surface of teeth adjacent to the interproximal defect should be free of extensive recession and marginal bone loss, with at least a 4 to 5 mm band of keratinized gingiva to allow for periosteal manipulation

Exclusion Criteria:

* Pregnant women
* Subjects had \<22 permanent teeth
* Having any given systemic disease
* Taking any type of medication and/or antibiotic therapy during the 3 months before the study
* Received periodontal treatment within the past 12 months
* Current or former smokers
ARAT for Reflux Disease After Peroral Endoscopic Myotomy in Patients With Achalasia

The peroral endoscopic myotomy for the treatment of achalasia is associated with a higher incidence of gastroesophageal reflux disease compared with Heller's myotomy. Remodeling of the esophagogastric junction with hybrid argon plasma could decrease the passage of gastric or gastroduodenal content into the esophagus.

Achalasia is the inability of the lower esophageal sphincter to relax in the context of dysfunction of esophageal peristalsis. Peroral endoscopic myotomy for the treatment of achalasia has an efficacy above 90%, being comparable with Heller's myotomy. The treatment of achalasia by peroral endoscopic myotomy is associated with a higher incidence of gastroesophageal reflux disease, compared with alternative therapies such as Heller's myotomy or pneumatic dilatation. Hybrid argon plasma at the level of the esophagogastric junction could generate remodeling of this region generating a partial stenosis and thereby decrease the passage of gastric or gastroduodenal content into the esophagus.

A clinical trial will be carried out, including all patients with achalasia, treated by peroral myotomy older than 18 years old, with abnormal acid exposure in the pHmetry test 3 months or more after treatment, who accept the management of ablation with hybrid argon plasma. To whom the ablation will be performed with Hybrid Argon Plasma and its effectiveness will be evaluated by clinical questionnaires, endoscopy and pHmetry measurement at the beginning, 3 months, 6 months and 12 months after the procedure.

Demographic and clinical data will be recorded in a data collection sheet, detailing the reflux questionnaire(GERDQ), Eckardt score, endoscopic findings of esophagitis according to Los Angeles classification and abnormal acid exposure in each evaluation. The data will be condensed into a database for subsequent statistical analysis and publication of results.

Eligibility Criteria:
Inclusion Criteria:

* Achalasia type I, II, III
* Treatment with POEM (Peroral Endoscopic Myotomy)
* Abnormal acid exposure (\>6%) in the 24h-pHmetry test more than three months after the procedure
* Signed informed consent

Exclusion Criteria:

* Patients who do not accept the treatment
* Previous antireflux surgery
* Previous Heller's Myotomy
* Hiatal hernia greater than 3 centimeters
* Hill's Classification Grade IV
* Pregnancy
* Patients with any contraindication for an endoscopy
* Patients with esophageal or gastric varices
Whole-Neck Computed Tomography Perfusion Scan in Imaging Patients With Head and Neck Tumors

This pilot clinical trial studies how well whole-neck computed tomography perfusion scans work in imaging patients with head and neck tumors. Diagnostic imaging procedures, such as whole-neck computed tomography perfusions scans, may provide more information about the blood supply to head and neck tumors which may help doctors plan better treatment.

PRIMARY OBJECTIVES:

I. To assess the difference in whole-neck computed tomography perfusion (WNCTP) parameters (blood volume \[BV\], blood flow \[BF\], capillary permeability \[CP\] and mean transit time \[MTT\]) between head and neck tumor masses (benign or malignant) and adjacent normal skeletal muscle within the same patient.

II. To assess whether the difference in WNCTP parameters between tumor masses and adjacent normal skeletal muscle is different between patients with benign tumor versus (vs.) malignant tumor.

III. To assess the correlation in WNCTP parameters between tumor masses and adjacent normal skeletal muscle.

IV. Determine if more suspicious cervical lymph nodes will be seen using the whole-neck coverage employed in WNCTP compared to the limited coverage of traditional neck CTP.

OUTLINE:

Patients undergo WNCTP scan over 2-3 minutes during standard of care computed tomography (CT).

After completion of study, patients are followed up within 2 days.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed or suspected head and neck tumor (benign or malignant)
* Scheduled for contrast CT (standard of care)
* No known allergies to contrast material

Exclusion Criteria:

* Known allergies to contrast material
* Pregnant or nursing
EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")

The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.

The objectives of this registry are to describe clinical and demographic characteristics, prescribing patterns, treatment patterns, and outcomes in participants treated with EndeavorRx in a real-world setting.

Patients and their caregivers will be informed about the registry as part of a series of product welcome emails following product activation. Patients/caregivers enroll into the study by providing their electronic informed consent (eConsent) and assent (eAssent). All data are captured electronically and securely through a commercial data capture platform. Participants can also invite their child's teacher to submit surveys of their observations of the child's ADHD symptoms for the study. Study activities are emailed to caregivers at baseline, 1, 2, 3, and 6-months after enrollment.

A valid and active EndeavorRx prescription is required to enroll. However, an active prescription throughout the entire 6 months of study participation is not required.

Eligibility Criteria:
Inclusion Criteria:

* Are prescribed EndeavorRx by their healthcare provider as part of routine clinical practice
* Provide informed consent/assent to participate in the registry

Exclusion Criteria:

* N/A
Dexmedetomidine and Delirium in Elderly Patients

Investigators investigates the effect of perioperative dexmedetomidine 0.5 ug/kg/hr followed by a postoperative continuous infusion fentanyl-based PCA(Patient-Controlled Analgesia) drug mixed with dexmedetomidine 0.2ug/kg/hr for two days on reducing postoperative delirium and postoperative rescue analgesics in elderly patients who undergo hip surgery. The other half of patients received fentanyl-based PCA only.

Elderly patients are susceptible to postoperative delirium. Delirium occurs in 10\~60% and is associated with longer hospital stays, increased costs, and morbidity. Postoperative delirium usually occurs 2\~3 days after surgery. Intraoperative infusion of dexmedetomidine lacks preventing postoperative delirium in elderly noncardiac major surgery.

We hypothesized postoperative dexmedetomidine for two days as a mixture drug of fentanyl-based PCA could reduce the incidence of postoperative delirium. We compared this effect with other control group who received fentanyl-based PCA only.

We also investigate EEG patterns of patients during emergence and compared the EEG patterns who developed delirium postoperatively in PACU(Postanesthesia care unit) or general ward. Dexmedetomidine has analgesic effect. We expected postoperative dexmedetomidine has benefits of opioid sparing effects.

Eligibility Criteria:
Inclusion Criteria: over 65 yrs old elderly patient who undergo elective hip surgery and ASA(The American Society of Anesthesiologists) physical status I-III

Exclusion Criteria:

history of dementia, drug abuser, hypersensitivity to dexmedetomidine, fentanyl, propofol, disable to speech, reject the clinical study, hemodynamic instability during surgery, an illiterate, pregnancy
Prevalence of IA and IGD Disorders Among Assiut University Students

identifying the Prevalence of internet addiction and internet gaming disorder among Assiut university students

Internet activities and technologies that are increasing rapidly have attracted young adults, leading to excessive use of the Internet and maladaptive Internet attitude known as "Internet addiction". The term "addiction", even traditionally utilized to describe a physical dependence of substances, has been applied to the excessive use of the Internet . Internet addiction disorder is expressed as too much computer use that contradicts daily activities and can harm daily function .

Internet gaming disorder (IGD) was included as a nonsubstance addiction in the appendix of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) published in 2013 by the American Psychiatric Association. The need to add IGD to this diagnostic manual was identified by an international expert working group that reviewed over 250 articles, some of which showed the detrimental effects of excessive gaming . As part of the DSM-5 approach to defining IGD, draft diagnostic criteria were proposed with some similarities to substance use disorders and added to the appendix of the DSM-5 manual, suggesting IGD was a condition warranting further research. The harmful consequences of excessive gaming were also recognized by the World Health Organization (WHO), and gaming disorder (GD) was included in their 2018 release of the 11th revision of the International Classification of Diseases (ICD-11) .

Eligibility Criteria:
Inclusion Criteria:

* Assiut university student Active Internet user since at least 1 year Willing to give consent and complete the questionnaire

Exclusion Criteria:

* Not willing to give consent and complete the questionnaire
Strict IGF-1 Control in Acromegaly

Acromegaly is a rare, chronic, and debilitating disease, usually caused by a benign tumor on the pituitary gland, which leads to excessive production of growth hormone (GH). GH excess in turn causes overproduction of another hormone called insulin-like growth factor-1 (IGF-1). IGF-1 levels are currently the most widely accepted measure of disease activity.

In Canada, medical therapy with a type of medicine called "somatostatin analogues" (SSA), such as octreotide and lanreotide, is recommended for treatment of acromegaly. However, studies have shown that a significant number of patients who take SSA medications alone remain with elevated levels of IGF-1 in their blood.

Another medication that is used to treat acromegaly is pegvisomant (PEGV), and the investigators plan to study whether strict control of IGF-1, by adding or optimizing the use of PEGV, results in a significant health benefits to patients who still have modestly high levels of IGF-1 in their blood.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients (at least 18 years old) with confirmed acromegaly whose IGF-I levels are persistently but modestly (1.0 ULN \< \[IGF-1 serum level\] \< 1.5 ULN) elevated following medical therapy such as SSA, PEGV, cabergoline alone or in combination.

Exclusion Criteria:

1. Progressive or recent visual field loss or optic chiasmal compression, or pituitary tumors within 2mm from the chiasm. Patients whose visual field loss, optic chiasmal compression or pituitary tumor has been stable for at least a year will be eligible.
2. Cranial nerve palsies or intracranial hypertension requiring tumour decompression surgery
3. Clinically significant hepatic disease and/or elevated liver enzymes (ALT, AST \> 3 x ULN)
4. Patients who have received pituitary surgery within one year prior to screening visit
5. Patients who have received radiation therapy within one year prior to screening visit
6. History of hypersensitivity to any components of Pegvisomant
7. Inability to fully comprehend the nature of the study or cooperate with study procedures
8. Pregnant / lactating women and subjects refusing to use adequate contraception to prevent pregnancy during the study.
9. Subjects unwilling or unable to self-administer medication on a daily basis
10. known or suspected alcohol / drug abuse
11. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation.
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.


Eligibility Criteria:
Inclusion Criteria:

* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
* Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis

Exclusion Criteria:

* Subject had previously received systemic or biologic anti-IL-12 therapy
* Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy
* Subject is taking or requires oral or injectable corticosteroids
* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
* Female subject who is pregnant or breast-feeding or considering becoming pregnant
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.

Melanoma is a serious form of skin cancer. If untreated, the melanoma can spread beyond the original affected tissue and invade distant tissue and organs. Treatment for metastatic melanoma includes medical treatments (chemotherapy or immunotherapy), surgery, or radiation therapy. MORAb-028 is a recombinant human immunoglobulin M (IgM) monoclonal antibody that recognizes a cell surface diacyl ganglioside named disialoganglioside (GD2). GD2 is overexpressed in tumors of neuro-ectodermal origin such as melanomas, neuroblastomas, small-cell lung carcinomas, and many sarcomas, while absent in most normal tissues. GD2 expression has been demonstrated in human melanoma and small cell lung cancer by thin layer chromatography and radiolabeled anti-GD2 antibody detection. It is hypothesized that one mode of action of MORAb-028 is complement-dependent cytotoxicity. Complement-dependent cytotoxicity is a mechanism for killing tumor cells in which an antibody bound to the target cell surface fixes complement, which results in assembly of the complement membrane attack complex that punches holes in the target cell membrane resulting in subsequent cell lysis. IgMs strongly bind to C1Q and robustly activate complement-dependent cytotoxicity. MORAb-028 is being developed as a potential therapy for GD2-positive tumors.

Eligibility Criteria:
Inclusion Criteria:

* Measurable metastatic melanoma that has failed standard therapy
* Males and females greater than or equal to 18 years of age
* Life expectancy of greater than or equal to 3 months

Exclusion Criteria:

* Significant cardiovascular impairment
* Clinically significant illness, medical condition, surgical history, or laboratory abnormality that could affect the safety of the subject or negatively impact the study results
* Chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to administration to MORAb-028